3:09 PM Abstract No. 337 Clinical outcomes and quality of life measures in the use of prostate artery embolization for prostates 50 to 80 g: a single-center analysis with 1-year follow-up

Abstract

To evaluate the efficacy and quality of life (QOL) impact of prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) for prostates size 50 to 80 g. 68 patients who underwent PAE for BPH with prostate size 50 to 80 g from January 2014 to May 2019 were evaluated as part of an IRB-approved retrospective analysis at a single institution. Patients with active urinary tract infection (UTI), renal failure, urinary retention, severe atherosclerosis and no follow-up at 3 or 6 months were excluded from the analysis. Mean patient age was 67.6 years, mean prostate volume was 64.9 g, mean pre procedure IPSS, QOL and PVR were 25.5, 4.8 and 137.2 mL. Patients were evaluated at 1, 3, 6 and 12 month intervals following PAE. Adverse events were recorded using the Clavien-Dindo classification. Three months after PAE, mean IPSS improved from 25.5 to 9.8 (↓62%, n = 50, P <0.001), mean QOL improved from 4.8 to 1.9 (↓60%, n = 50, P <0.001), mean prostate size decreased 46.3 g (↓29%, n = 53, P <0.001) and mean PVR decreased to 48.7 mL (↓65%, n = 17, P <0.01). At six month follow-up with mean IPSS was 9.9 (↓61%, n = 37, P <0.001) and mean QOL was 1.9 (↓60%, n = 36, P <0.001). At 12 months, mean IPSS was 10.3 (↓60%, n = 29, P <0.001), mean QOL was 1.9 (↓65%, n = 27, P <0.001) and mean prostate volume was 44.6 g (↓31%, n = 20, P = 0.001). 37.5% of patients had grade I events occurred, self-limited. PAE achieved a clinically and statistically significant reduction in prostate size, IPSS score and improved QOL, in patients with prostate sizes 50 to 80 g. PAE is an effective treatment for BPH in patients with medium size glands and lower urinary tract symptoms.